Boston, MA – October 2026 – The burgeoning biotech hub of Boston is set to host the 18th Annual Outsourcing in Clinical Trials (OCT) New England conference this October, a pivotal event where industry leaders will converge to dissect the most pressing challenges confronting the global clinical trial landscape. At the forefront of these concerns is the escalating difficulty in recruiting and retaining study participants, a bottleneck that threatens to stifle innovation and delay the delivery of life-saving therapies to patients.
n
Scheduled for October 27th-28th, 2026, the conference will bring together a diverse spectrum of stakeholders from the biopharmaceutical sector, including pharmaceutical giants, contract research organizations (CROs), technology providers, and regulatory experts. The agenda is meticulously crafted to address the complex realities of modern drug development, with a particular emphasis on innovative strategies and operational efficiencies required to navigate the current challenging environment.
n
The Unfolding Recruitment Conundrum: A Global Imperative
n
The central theme resonating throughout this year’s OCT New England conference is the "growing global enrolment challenge." This critical issue will be illuminated in an opening Q&A session featuring Kenneth Getz, a respected figure and executive director at the Tufts Center for the Study of Drug Development. The rapid advancements in therapeutic areas, particularly in oncology and rare diseases, have spurred an unprecedented surge in the number of clinical trials initiated. However, this proliferation of research has not been met with a commensurate increase in patient availability. Consequently, a significant number of trials are being terminated prematurely due to an inability to recruit sufficient participants, representing a substantial waste of resources and a delay in bringing potentially life-changing treatments to market.
n
Getz’s presentation is expected to provide a robust, data-driven quantification of the global recruitment challenge, offering attendees a clear understanding of its current scale and trajectory. More importantly, he will delve into actionable insights for trial sponsors, outlining how to adapt trial designs to become more patient-centric and thus more appealing to potential participants. Following this, Getz will moderate a keynote panel that will explore broader, systemic strategies being implemented across the industry to foster more agile and bespoke trial designs, moving away from rigid, one-size-fits-all approaches.
n
A Multifaceted Approach: Navigating the Complexities of Clinical Operations
n
The two-day event will be structured around three distinct, yet interconnected, thematic streams, ensuring comprehensive coverage of the critical elements shaping clinical trial operations:
n
- n
- Outsourcing and Clinical Operations: This stream will delve into the evolving landscape of outsourcing partnerships, exploring best practices for selecting and managing Contract Research Organizations (CROs) and other vendors. Discussions will focus on optimizing operational efficiency, ensuring quality control, and adapting to changing regulatory requirements.
- Data, Artificial Intelligence (AI), and Clinical Innovation: Recognizing the transformative potential of technology, this stream will examine the integration of data analytics and AI into clinical trial design, execution, and monitoring. Sessions will explore how these tools can enhance patient identification, streamline data collection, and improve trial outcomes.
- Biotech Strategy: This stream will provide a high-level overview of the strategic considerations for biotech companies navigating the complex drug development pathway. Topics will include regulatory pathways, market access strategies, and the crucial role of patient advocacy.
n
n
n
n
Across these streams, an array of speakers representing leading pharmaceutical companies and innovative vendors will deliver talks on a variety of critical topics. These include the latest regulatory developments impacting clinical research, the increasing imperative of patient-centricity in trial design and execution, and the far-reaching implications of geopolitical shifts on global clinical trial conduct.
n
Industry Voices: Insights from Key Leaders
n
The conference agenda features a distinguished lineup of speakers who will offer invaluable perspectives on the industry’s most pressing issues. Aditya Kotta, Vice President of Business Development at Novotech, is slated to present on the latest clinical development trends and opportunities within the dynamic US and Chinese markets, highlighting the nuances and strategic considerations for global drug development.
n
Furthermore, Akash Patel, Senior Director at GSK, and Vasudev Bhupathi, Director of Pharmacovigilance at Moderna, will co-host an engaging "Ask the Experts" session. This interactive segment will provide attendees with a direct opportunity to engage with leading professionals on the implications of the new International Council for Harmonisation (ICH) E6(R3) guidelines. These revised guidelines are set to significantly influence the conduct of clinical trials, emphasizing a more risk-based and flexible approach, and understanding their impact is crucial for all stakeholders.
n
The Ascendancy of AI: Promise and Pitfalls
n
As anticipated, Artificial Intelligence (AI) will be a dominant theme throughout the OCT New England conference, reflecting its growing influence in revolutionizing clinical trial processes. Kelly Butler, Ethics and Compliance Partner at Takeda Pharmaceutical, will lead an interactive session that critically examines the ethical considerations and practical limitations of AI in clinical research. Her session will focus on the potential for misrepresentation, inherent biases within data, and the crucial understanding of data limitations that can impact the conclusions drawn from AI-driven analyses.
n
Complementing this, a high-level panel discussion will bring together representatives from esteemed organizations such as Tufts University, Novo Nordisk, and Alnylam Therapeutics. This panel will explore the evolving operational models within sponsor organizations as they increasingly integrate AI capabilities. The discussion will also address the adoption of more risk-based and centralized approaches to study monitoring, a shift facilitated by the advanced capabilities offered by AI and other technological innovations.
n
Looking Ahead: Regulatory Evolution and Patient Inclusivity
n
The second day of the conference will continue to explore these critical themes, with sessions dedicated to AI-enabled study monitoring, strategic approaches to selecting the right CRO partners, and other key aspects of optimizing clinical trial operations.
n
The conference will culminate with a keynote presentation by Kevin Bugin, Head of Global Regulatory Policy and Intelligence at Amgen. Bugin, who previously served as Deputy Director of Operations at the U.S. Food and Drug Administration (FDA), is expected to provide a comprehensive overview of how FDA priorities are shaping the future of clinical progress. His insights will illuminate the agency’s drive towards achieving greater speed, broader reach, and enhanced patient inclusivity in clinical development, offering a forward-looking perspective on the regulatory landscape.
n
The 18th Annual Outsourcing in Clinical Trials New England 2026 conference promises to be an essential forum for industry professionals seeking to understand and address the multifaceted challenges in clinical trials, with a particular focus on overcoming the persistent hurdles in participant recruitment and retention.
n
A detailed agenda for the conference can be accessed here. The event is hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology.
n
For those interested in attending or sponsoring the Outsourcing in Clinical Trials New England conference, further information can be obtained by completing the form provided by the Arena International team.
nnnnn
